Although current pharmacotherapies for T2DM and AS—such as insulin, glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs), sodium-glucose co-transporter 2 inhibitors (SGLT2is), and statins—have diversified in recent years, several clinical challenges remain [7]. This evidence concerns the gene GCG and type 2 diabetes mellitus.